BioSpace News Archive

Intrommune Therapeutics has announced an expanded partnership with Circuit Clinical, a leading Integrated Research Organization (IRO). Based on this deal, Circuit Clinical will oversee the early clinical development of Intrommune’s lead drug, INT301, including a Phase 1b study planned for Q4 2020 and Q1 2021. “We are excited about the opportunity to partner with Circuit Clinical to support the development of peanut INT301,” said Michael Nelson, CEO

Minnetronix Medical, which partners with companies throughout the world to design, develop and manufacture medical device technology, today announced that it has been awarded a National Institutes of Health (NIH) granti for continued study of its proprietary Neurapheresis™ Cerebrospinal Fluid Treatment Platform

Palladio Biosciences, Inc. (Palladio), a privately-owned, clinical stage biopharmaceutical company developing medicines for orphan diseases of the kidney, announced today the results of a study that investigated the use of lixivaptan in a patient with autosomal dominant polycystic kidney disease (ADPKD) who could not tolerate a different vasopressin V2 receptor antagonist, tolvaptan. The presentation will be made as an ePos

The Manhattan-based fertility center Reproductive Medicine Associates of New York (RMA of New York) presented 31 scientific abstracts at the 76th annual meeting of the American Society for Reproductive Medicine (ASRM)

ColdQuanta, the quantum atomics company, today announced “Albert,” its quantum matter system on the cloud. With Albert, users can explore fundamental quantum phenomena such as tunneling and superposition by generating, manipulating, and experimenting with ultracold matter.

Humanetics Corporation (Humanetics) presented at the 2020 Annual Meeting of the Radiation Research Society (RRS), held virtually October 18 th through the 21 st . Artur Serebrenik, Ph.D., of Humanetics presented data related to the Company’s medical countermeasure for radiation exposure, BIO 300 Oral Powder. The data describe the developme

Revenues totalling €9.4m over the first three quarters 2020, higher than 2019 yearly revenue (€9m) Q3 revenue of €3.5m, a 50% increase compared to Q3, 2019 Order backlog of €50.7m Cash and cash equivalents of €17.3m

Vuzix® Corporation (NASDAQ: VUZI), (“Vuzix” or, the “Company”), a leading supplier of Smart Glasses and Augmented Reality (AR) technology and products, announced it has partnered with the Children of War Foundation (COWF) to further the access to medical and surgical education through the use of Vuzix M400 Smart Glasses to con

IntraOp Medical Corporation announced today the installation of the first electron, intraoperative radiotherapy system (IORT) in Canada, at the Centre hospitalier de l’Université de Montréal (CHUM) in Quebec.

OliX Pharmaceuticals, Inc . (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that Dong Ki Lee, Ph.D., founder and Chief Executive Officer of the Company, will present its platform technology and discuss the potential utility of Asymmetric small interfering RNA (asiRNA), Cell-Penetrating Asymmetric Interfering RNA (cp-asiRNA) and GalNAc-asiRNA at the 5 th Annual OPT Congress Oligonucleotide & Precision